Tagged with Clinical Trials,

Canada Janice Murray, president of Novartis Pharmaceuticals Canada Inc., highlights the track record of excellence Novartis has enjoyed in Canada as the second largest pharma affiliate in the country, the challenge of adapting to an increasingly uncertain market access environment, and the exciting initiatives through which Novartis is delivering innovations and…

Tunisia Chokri Jeribi, country chair of Sanofi Tunisia since 2016, is responsible for the development and market leadership hold of Sanofi’s affiliate in Tunisia. In this interview he stresses the importance that clinical trials activities for both the company and the country. Additionally, Jeribi documents the unique collaboration system with local…

Austria Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations. Furthermore, he points out the factors influencing the influx of innovative drugs into Austria, especially in rare diseases, and highlights…

Austria Prof. Ruth Ladenstein, executive director of the Medicines for Children Research Organisation (OKIDS) in Austria, explains OKIDS’ drive to ensure drugs are paediatric specific by conducting child-specific clinical trials. Furthermore, she highlights the challenges associated with achieving a participating child’s consent and defines what must be done to gain governmental…

Austria Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia, willing volunteers and educated medical personnel balanced against a backdrop of economic stability. “Austria should be proud of the abundance…

Colombia Guillermo Browne, General Manager at MSD Colombia, reveals the strategic importance of the Colombian affiliate, hosting a global data management centre and regional pharmacovigilance operations, while highlighting the company’s commitment to continue advancing the therapeutic value of care and the clinical research landscape in Colombia. With 70 years of presence…

Bulgaria Deyan Denev, Executive Director of the Association of the Research-Based Pharmaceutical Manufacturers in Bulgaria (ARPharM), shares a clear overview of the role of innovative pharmaceutical players within Bulgaria, and the association’s commitment to working with government to enlarge patients’ access to innovative medicines. How has the overall situation for innovative…

Austria Prof. Dr. Robin Rumler, country manager of Pfizer Austria, discusses the evolution of their operations, especially since taking over the TBE and meningitis vaccine production plant, as well as the challenges facing the entire Austrian healthcare system today. Furthermore, he provides solutions to create a sustainable future for Austrian healthcare,…

Hong Kong Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make it a strong contender in clinical research.   Hong Kong is an important piece of our global R&D landscape Scott…

Hong Kong Novartis Hong Kong general manager Dorine Leung and oncology head Sian Ng discuss the company’s restructuring, dividing the oncology business unit from the pharmaceutical division. In addition, they share their insights on what makes Hong Kong a destination for world-class clinical trials. Novartis recently underwent a major restructuring with the…

Hong Kong Henry Yau, MD and Honorary Assistant Professor at the University of Hong Kong Clinical Trials Centre (HKU-CTC) discusses the center’s development, the diverse range of services it offers, and the clinical trials environment in Hong Kong. Having been with the organization since nearly the beginning from 2000, how have you…

Mexico According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment in this area. As Mexico currently only invests 1.8 percent of its GDP into R&D, there is clearly still a…